Oramed Pharmaceuticals Stock Intrinsic Value – Oramed Pharmaceuticals’ P3 Type 2 Diabetes Trial Fails to Meet Expectations
January 30, 2023
Trending News 🌧️
Oramed Pharmaceuticals Stock Intrinsic Value – Oramed Pharmaceuticals ($NASDAQ:ORMP) recently announced the results of its Phase 3 trial for an oral insulin product designed to treat type 2 diabetes. Unfortunately, the trial failed to meet expectations and the company’s stock value took a hit as a result. This has raised questions about the impact of the trial failure on Oramed Pharmaceuticals and the future of its oral insulin product. Oramed Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing innovative drug delivery systems for treatments in diabetes, obesity, and gastroenterology. The company’s lead product is an oral insulin capsule, which is designed to provide a safe and effective treatment for type 2 diabetes. Unfortunately, the Phase 3 trial failed to meet expectations and the results showed that the oral insulin capsule was not as effective as anticipated.
As a result, Oramed’s stock value dropped significantly and the company has been forced to reassess its plans for the oral insulin product. The failure of the trial has cast doubts on the effectiveness of the product and whether or not it can be approved by the FDA. The impact of Oramed Pharmaceuticals’ failed P3 trial cannot be overstated. The failure has brought into question the viability of the oral insulin product and put a damper on the company’s prospects for success. Oramed will need to reassess its plans for the product and determine how to move forward. In the meantime, investors will be closely watching how Oramed responds to this setback and if it is able to make progress in developing a successful oral insulin product.
Share Price
This has caused a major negative media reaction and has sent the company’s stock into a downward spiral. On Tuesday, Oramed Pharmaceuticals’ stock opened at $2.2 and closed at $2.0, a plunge of 10.2% from its previous closing price of $2.2. This sharp decline in their stock prices has caused a lot of investors to panic and has made many wary of investing in the company’s future prospects. This news comes as a major disappointment to shareholders and potential investors who had high hopes for the company’s P3 Type 2 Diabetes Trial. The trial was expected to be a major breakthrough in diabetes research and could have potentially revolutionized the way diabetes is treated and managed. Unfortunately, it failed to meet expectations and has caused investors to lose faith in Oramed Pharmaceuticals. It is still too early to tell what the lasting effect of this failure will be on the company’s stock and prospects.
However, it is clear that the negative press surrounding this trial failure has had a significant impact on the company’s stock prices. Investors will likely remain wary until the company can prove that it is still capable of delivering results in the future. Until then, they will likely remain cautious when considering investing in Oramed Pharmaceuticals. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Oramed Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 0.9 | -11.67 | -941.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Oramed Pharmaceuticals. More…
| Operations | Investing | Financing |
| -11.12 | -99.25 | 60.57 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Oramed Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 177.82 | 11.21 | 4.36 |
Key Ratios Snapshot
Some of the financial key ratios for Oramed Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 2.5% | – | -983.6% |
| FCF Margin | ROE | ROA |
| -1231.3% | -5.4% | -4.3% |
VI Analysis – Oramed Pharmaceuticals Stock Intrinsic Value
Oramed Pharmaceuticals is a company that has potential for long-term growth. The VI app offers a simplified analysis of the company’s fundamentals, and based on that analysis, the fair value of Oramed Pharmaceuticals’ shares is estimated to be $12.7. At present, Oramed Pharmaceuticals’ stock is trading at $2.0, which is an 84% discount compared to the estimated fair value. This suggests that Oramed Pharmaceuticals’ stock is significantly undervalued, and may be an attractive investment for those looking for long-term growth potential. Analyzing a company’s fundamentals is important for investors who are looking to make informed decisions about investing in a particular company. The VI app provides a comprehensive overview of the financials, including cash flow, debt, earnings, and equity. This information can be used to determine whether or not the company is worth investing in. In the case of Oramed Pharmaceuticals, the VI app suggests that the stock is undervalued and may be a good long-term investment for those looking for growth potential. It is important to do research before investing in any company. Investors should review all of the available financial information and consider their own risk tolerance when making decisions. Additionally, it may be beneficial to seek advice from a financial advisor before investing in any company. Investing in Oramed Pharmaceuticals may be a good option for those looking for long-term growth potential, but it is important to do research and make sure it is the right fit for an individual’s investment goals. More…
VI Peers
The company has several competitors, such as Genovate Biotechnology Co Ltd, NervGen Pharma Corp, and Beijing Konruns Pharmaceutical Co Ltd. The competition between these companies is fierce, as each company tries to develop the best products and technologies to offer to their customers.
– Genovate Biotechnology Co Ltd ($TPEX:4130)
Genovate Biotechnology Co Ltd has a market cap of 2.48B as of 2022. The company’s Return on Equity is 0.44%. Genovate Biotechnology Co Ltd is a biotechnology company that focuses on the research and development of new drugs and therapies. The company’s main products are anticancer drugs and vaccines.
– NervGen Pharma Corp ($TSXV:NGEN)
NervGen Pharma Corp is a biotechnology company that focuses on the development of therapies for nervous system injuries and degenerative diseases. The company has a market capitalization of 102.45 million as of 2022 and a return on equity of -90.61%. The company’s products are in various stages of development, including a product that is in clinical trials for the treatment of spinal cord injuries.
– Beijing Konruns Pharmaceutical Co Ltd ($SHSE:603590)
Beijing Konruns Pharmaceutical Co Ltd has a market cap of 4.31B as of 2022. The company’s Return on Equity (ROE) is 3.39%.
Beijing Konruns Pharmaceutical Co Ltd is a pharmaceutical company that manufactures and sells pharmaceutical and medical products in China. The company’s products include prescription drugs, over-the-counter drugs, and traditional Chinese medicines. Beijing Konruns Pharmaceutical Co Ltd is headquartered in Beijing, China.
Summary
Investors should be aware that Oramed Pharmaceuticals has recently suffered a setback in its Phase 3 Type 2 Diabetes Trial, as the results did not meet expectations. This has caused a negative media response and the company’s stock price has dropped accordingly. Despite this, the company remains focused on its mission of developing innovative oral drug delivery systems, making it a viable option for investors who are seeking to capitalize on the potential of this sector. Investors should be aware of the risks, but with the right research, may find Oramed Pharmaceuticals to be a rewarding long-term investment.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
